Relmada Therapeutics Inc Earnings Call Transcript Highlights Strategic ...

RLMD Stock  USD 0.47  0.01  2.08%   
About 57% of all Relmada Therapeutics' shareholders are looking to take a long position. The analysis of overall sentiment of trading Relmada Therapeutics stock suggests that some investors are interested at this time. The current market sentiment, together with Relmada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Relmada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Research and Development Expense 13.3 million in Q1 2024, down from 15.9 million in Q1 2023.General and Administrative Expense 9.7 million in Q1 2024, dow

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Relmada Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Relmada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Relmada Therapeutics Fundamental Analysis

We analyze Relmada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relmada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relmada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Book

Price To Book Comparative Analysis

Relmada Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Relmada Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Relmada Therapeutics stock to make a market-neutral strategy. Peer analysis of Relmada Therapeutics could also be used in its relative valuation, which is a method of valuing Relmada Therapeutics by comparing valuation metrics with similar companies.

Peers

Relmada Therapeutics Related Equities

NAMSNewAmsterdam Pharma   41.41   
0%
100.0%
CSBRChampions Oncology   6.76   
0%
16.0%
STTKShattuck Labs   4.00   
0%
9.0%
THRDThird Harmonic   2.69   
0%
6.0%
PMVPPmv Pharmaceuticals   0.63   
0%
1.0%
RVMDRevolution Medicines   0.53   
0%
1.0%
CYTKCytokinetics   0.1   
0%
1.0%
BCYCBicycle Therapeutics   0.90   
2.0%
0%
DYNDyne Therapeutics   1.19   
2.0%
0%
ELYMEliem Therapeutics   1.90   
4.0%
0%
EWTXEdgewise Therapeutics   2.58   
6.0%
0%
NUVBNuvation Bio   3.21   
7.0%
0%
IPSCCentury Therapeutics   4.08   
9.0%
0%
RAPTRAPT Therapeutics   6.84   
16.0%
0%

Complementary Tools for Relmada Stock analysis

When running Relmada Therapeutics' price analysis, check to measure Relmada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relmada Therapeutics is operating at the current time. Most of Relmada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relmada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relmada Therapeutics' price. Additionally, you may evaluate how the addition of Relmada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Fundamental Analysis
View fundamental data based on most recent published financial statements